Reed, Shelby D

Dillingham, Peter

Briggs, Andrew H

Veenstra, David L

Sullivan, Sean D

2003

Pharmacy and therapeutics committees commonly cite a lack of generalizability as a reason for not incorporating cost-effectiveness information into decision making. To address this concern, many committees undertake site-specific economic evaluations, which are often limited by small sample sizes and non-randomized designs. We show how 2 complementary approaches were used to minimize these limitations in an economic evaluation of abciximab at 1 institution. Using a propensity score methodology, we selected patients who did not receive abciximab for the comparison cohort. Then, we adopted a Bayesian, hierarchical, random-effects model to integrate site-specific and clinical trial data. We applied the posterior distributions of effectiveness with local cost data in a traditional decision-analytic model. In 74% of the simulations, abciximab was cost-effective at 1 institution at the $50,000 per life year saved threshold, assuming a 50:50 split of patients undergoing coronary stenting and angioplasty. Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations.

Medical Decision Making, 23(3), p. 252-264

1552-681X

0272-989X

https://hdl.handle.net/1959.11/15586

Sage Publications, Inc

A Bayesian Approach to Aid in Formulary Decision Making: Incorporating Institution-Specific Cost-Effectiveness Data with Clinical Trial Results

Journal Article

Publication